Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_4
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Recruiting2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 43 (75.0%)

Trials by Status

completed125%
recruiting250%
unknown125%

Recent Activity

2 active trials
Showing 4 of 4
completedphase_4

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
recruitingphase_4

OnabotulinumtoxinA for Trigeminal Neuralgia

NCT06216886
recruitingphase_4

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

NCT05806164
unknownphase_3

Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin

NCT03758235

Clinical Trials (4)

Showing 4 of 4 trials
NCT05308979Phase 4

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Completed
NCT06216886Phase 4

OnabotulinumtoxinA for Trigeminal Neuralgia

Recruiting
NCT05806164Phase 4

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Recruiting
NCT03758235Phase 3

Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4